A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523690-41-00

Acronym

D9180C00015

Enrollment

Registered

2025-12-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Brief summary

Adverse events, laboratory assessments. Assessments related to adverse events include: • Occurrence/frequency • Relationship to IMP as assessed by Investigator • Intensity • Seriousness • Death • Adverse events leading to discontinuation of IMP • Other significant AEs

Interventions

DRUGTozorakimab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Adverse events, laboratory assessments. Assessments related to adverse events include: • Occurrence/frequency • Relationship to IMP as assessed by Investigator • Intensity • Seriousness • Death • Adverse events leading to discontinuation of IMP • Other significant AEs	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026